Multiple Myeloma Diagnostic Criteria (IMWG)

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
diagnosis
—امتیاز
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Not Diagnostic0–0
  • Multiple Myeloma1–1
Direct Clinical Answer

The Multiple Myeloma Diagnostic Criteria (IMWG) calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include clonal plasma cells bone marrow. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Diagnoses multiple myeloma according to the International Myeloma Working Group (IMWG) criteria, including traditional CRAB criteria and newer SLiM biomarkers.

Clinical Indication

The Multiple Myeloma Diagnostic Criteria (IMWG) is indicated for bedside clinical practice to support Diagnoses multiple myeloma according to the International Myeloma Working Group (IMWG) criteria, including traditional CRAB criteria and newer SLiM biomarkers.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.

Limitations & Contraindications

Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.

Clinical Pearls & Action Plan

Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Early treatment may prevent progression to symptomatic multiple myeloma.

Formula & Variables:

Multiple Myeloma Diagnosis = (Clonal plasma cells ≥10% OR Biopsy-proven plasmacytoma) AND ≥1 myeloma defining event (CRAB criteria: Hypercalcemia, Renal insufficiency, Anemia, Bone lesions; OR SLiM biomarkers: ≥60% plasma cells, Light chain ratio ≥100, >1 MRI focal lesion)

Input Parameters

NameTypeRequiredDescription
clonal_plasma_cells_bone_marrowstringYesClonal bone marrow plasma cells ≥10%
biopsy_proven_plasmacytomastringYesBiopsy-proven bony or extramedullary plasmacytoma
hypercalcemiastringYesHypercalcemia: Serum calcium >1 mg/dL above normal or >11 mg/dL
renal_insufficiencystringYesRenal insufficiency: Creatinine clearance <40 mL/min or serum creatinine >2 mg/dL
anemiastringYesAnemia: Hemoglobin >2 g/dL below normal or <10 g/dL
bone_lesionsstringYesBone lesions: ≥1 osteolytic lesion on imaging
plasma_cells_60_percentstringYesClonal bone marrow plasma cells ≥60%
light_chain_ratiostringYesInvolved:uninvolved serum free light chain ratio ≥100
focal_mri_lesionsstringYes>1 focal lesion on MRI

Score Interpretation & Guidance

RangeStageDescription
0–0Not DiagnosticCriteria not met for multiple myeloma
1–1Multiple MyelomaCriteria met for multiple myeloma

Evidence-Based References (EBM)

  • Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5.DOI: 10.1016/S1470-2045(14)70442-5
  • Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.DOI: 10.1016/S1470-2045(16)30206-6
  • Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267.DOI: 10.1200/JCO.2015.61.2267

Related calculators